In addition to stimulating GH release, GH secretagogues such as GH-releasing peptide-6 (GHRP-6) stimulate small amounts of ACTH and PRL release. Although the effects on ACTH have recently been studied, there is little information about the effects of GHRP-6 on PRL. We have now studied GHRP-6-induced GH and PRL release and their regulation by estrogen (E 2 ) in anesthetized male and female rats and in GH-deficient dwarf (dw/dw) rats that maintain high pituitary PRL stores and show elevated hypothalamic GH secretagogue receptor expression. Whereas GHRP-6 (0.1-2.5 g, iv) did not induce PRL release in normal male or female rats, significant PRL responses were observed in dw/dw females. These responses were abolished by ovariectomy and could be strongly induced in male dw/dw rats by E 2 treatment. These effects could be dissociated from GHRP-6-induced GH release in the same animals, but not from PRL release induced by TRH, which was also abolished by ovariectomy and induced in males by E 2 treatment. However, the effects of GHRP-6 on PRL were unlikely to be mediated by TRH because in the same animals, TSH levels were unaffected by GHRP-6 whereas they were increased by TRH. The increased PRL response could reflect an increase in GH secretagogue receptor expression that was observed in the arcuate and ventromedial nuclei of E 2 -treated rats. Our results suggest that the minimal PRL-releasing activity of GHRP-6 in normal rats becomes prominent in GH-deficient female dw/dw rats and is probably exerted directly at the pituitary; these GHRP-6 actions may be modulated by E 2 at both hypothalamic and pituitary sites. (Endocrinology 139: 3590 -3596, 1998) G H secretagogues (GHSs), developed from the prototype hexapeptide GH-releasing peptide-6 (GHRP-6), are potent releasers of GH in animals and man (1-4) and act both at the pituitary and in the hypothalamus via a novel receptor that has recently been cloned and sequenced (5-7). The distribution (8) and regulation by GH (9) of this GHS receptor (GHS-R) in the rat hypothalamic arcuate nucleus (ARC) support earlier evidence suggesting that GHSs release GH in part via the activation of ARC neurons (10). However, GHS-R expression is seen in several other central nervous system sites not obviously involved in the regulation of GH (8), suggesting that GHSs may have other functions.
G
H secretagogues (GHSs), developed from the prototype hexapeptide GH-releasing peptide-6 (GHRP-6), are potent releasers of GH in animals and man (1) (2) (3) (4) and act both at the pituitary and in the hypothalamus via a novel receptor that has recently been cloned and sequenced (5) (6) (7) . The distribution (8) and regulation by GH (9) of this GHS receptor (GHS-R) in the rat hypothalamic arcuate nucleus (ARC) support earlier evidence suggesting that GHSs release GH in part via the activation of ARC neurons (10) . However, GHS-R expression is seen in several other central nervous system sites not obviously involved in the regulation of GH (8) , suggesting that GHSs may have other functions.
Although the endocrine effects of GHSs are relatively specific for GH release, this specificity is not absolute. Most of the GHSs tested also release small but significant amounts of ACTH and PRL (4, (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Earlier studies have suggested that these secretagogues do not act directly on the corticotrophs (21) , but release ACTH indirectly, again via a hypothalamic action (22) , possibly involving CRH or AVP (16) . GHSs also stimulate small but significant amounts of PRL release in human subjects (12, 13, 15, 20, 23, 24) , but the mechanisms involved are unknown, largely because the PRL responses are minimal or even absent in conscious experimental animals (14, 25) and thus difficult to study.
We wished to examine the PRL-releasing activity of GHRP-6 in the rat. In addition to normal male and female rats, we chose to study GH-deficient dwarf (dw/dw) rats (26) , because these show increased hypothalamic GHS-R expression (9) , respond robustly to GHSs (27) , and maintain high pituitary PRL stores despite profound GH deficiency (26, 28) . Whereas GHRP-6 had little effect on PRL release in normal rats of either sex, more consistent PRL responses were observed in dw/dw females. Furthermore, PRL responses to GHRP-6 were abolished in dw/dw females by ovariectomy and were induced in dw/dw males by treatment with estrogen (E 2 ), which also increased their hypothalamic GHS-R expression. Thus, GHRP-6 does release PRL in the rat, but this response varies markedly with GH status and the gonadal steroid milieu.
Materials and Methods

Animals and treatments
All experiments were carried out under our institutional and national ethical guidelines. Normal and dwarf (dw/dw) rats (26) from the same (NIMR:AS) strain were housed under controlled conditions (22 C; 12-h light, 12-h dark cycle) with food and water ad libitum. Animals were studied at 35-40 days of age or at 10 weeks of age in different experiments. Some dw/dw rats were ovariectomized (Ovx) under halothane anesthesia at 8 weeks of age and studied 2 weeks later, whereas controls were sham operated (29) . Other groups of normal or dw/dw male rats were implanted sc with controlled release pellets (Innovative Research of America, Toledo, OH) delivering estradiol (E 2 ) at 25 g/day for 2 weeks, as previously described (29) . Controls for these experiments underwent a sham implant procedure.
castle, UK), GH-releasing hormone [human GHRH-(1-29)NH 2 ], and GHRP-6 (Ferring, Malmö , Sweden) were dissolved in saline containing 0.05% BSA, diluted in heparinized saline, and injected in 100 l, flushed in with 100 l saline. Peptide doses and group sizes are detailed in the text or figure legends. For each peptide injection, samples of blood were withdrawn before and 5 and 15 min after injection. A period of 3 h was allowed between injections, which were given consecutively to the same animals, as detailed in the figure legends. Blood samples were centrifuged, and the plasma was separated and frozen for hormone measurements. RIAs for GH, PRL, and TSH were performed on 25-l aliquots as previously described (28, 30) , using reagents provided by the NIDDK, and the results were expressed as nanograms per ml in terms of the NIDDK standards: GH RP-2, PRL RP-3, and TSH RP-3.
In situ hybridization for GHS-R
Rats were killed by an ip overdose of Sagatal, and the brains were removed, frozen on dry ice, and stored at Ϫ70 C. Sections were cut at Ϫ16 C, thaw-mounted onto gelatin-and chrome alum-coated slides, and stored at Ϫ70 C until use. In situ hybridization for GHS-R was performed on 12-m coronal brain sections through the ARC and ventromedial nuclei (VMN) using full-length 35 S-labeled GHS-R antisense or sense control riboprobes, and the autoradiographic images were analyzed densitometrically using the program Image exactly as previously described (9) . Comparisons were made on sections from all animals exposed concurrently.
Statistical comparisons
Unless otherwise stated, results are expressed as the mean Ϯ sem. Groups were compared by Student's t test or ANOVA followed by Student-Newman-Keuls test for multiple comparisons, as appropriate. Differences with P Ͻ 0.05 were considered significant. Figure 1 shows the PRL and GH responses in groups of six prepubertal female rats of both normal (AS) and dw/dw strains given three different doses (0.1-2.5 g) of GHRP-6. GHRP-6 had no effect on PRL release in normal AS females, whereas dw/dw females showed a greater PRL response to GHRP-6, which was significant at the lowest dose tested (Fig.  1A) . This was not seen in GH responses to GHRP-6, which were lower in dwarves but increased dose dependently in both strains (Fig. 1B) . Similar results were obtained when GHRP-6 was given to groups of adult female rats (not shown), but no PRL responses to GHRP-6 were observed in male rats of either strain despite their marked GH responses to GHRP-6 (see below; Fig. 2) .
Results
In another experiment, GH and PRL responses to GHRH were examined in groups (n ϭ 5-6) of anesthetized normal and dw/dw prepubertal female rats. GHRH (100 ng, iv) stimulated a large release of GH in both strains (from 7.1 Ϯ 1.1 to 345 Ϯ 26 ng/ml and from 9.1 Ϯ 1.7 to 57 Ϯ 7.7 ng/ml; P Ͻ 0.005 in AS vs. dw/dw animals, respectively) without affecting PRL release in either strain (from 2.3 Ϯ 0.6 to 1.5 Ϯ 0.5, and from 2.1 Ϯ 0.4 to 2.6 Ϯ 0.5 ng/ml PRL; not significant). Thus, the PRL response to GHRP-6 is not simply a nonspecific response accompanying a large GH release in dw/dw rats.
Effects of E 2 treatment on GH and PRL release
The effects of E 2 treatment on PRL and GH responses to GHRP-6 and TRH were compared in groups of young male normal and dw/dw rats (n ϭ 6), and the results are shown in Fig.  2 . PRL release was completely refractory to GHRP-6 and TRH in untreated males of either strain (Fig. 2, A and B ). E 2 treatment raised baseline PRL levels in all groups. PRL release in normal males remained unresponsive to GHRP-6 after E 2 treatment, but showed small responses to TRH ( Fig. 2A) , whereas dw/dw males treated with E 2 showed very large PRL responses to both GHRP-6 and TRH (Fig. 2B ). In the same samples, GH release was stimulated by GHRP-6 in both normal and dw/dw rats (Fig.  2 , C and D). E 2 treatment had no effect on GHRP-6-induced GH release in normal rats, but reduced the GH response in dw/dw rats. TRH did not affect GH release in dw/dw males with or without E 2 treatment (Fig. 2D) .
Similar results were obtained when the same experiment was repeated in adult rats (n ϭ 6/group). Adult dw/dw rats treated with E 2 showed reduced GH responses to GHRP-6, but dramatically increased PRL responses to both GHRP-6 and TRH [from 94.0 Ϯ 32 to 389 Ϯ 67 ng/ml (P Ͻ 0.005) and from 48.9 Ϯ 7.5 to 570 Ϯ 48 ng/ml (P Ͻ 0.0001)]. E 2 treatment did not induce PRL responses to GHRP-6 in adult normal males (from 36.3 Ϯ 2.9 to 38.5 Ϯ 4.8 ng/ml); their PRL responses to TRH increased, but this difference just failed to reach statistical significance (from 21.6 Ϯ 3.9 to 124 Ϯ 48.8; P ϭ 0.06).
Effects of ovariectomy on GH and PRL release
As the PRL responses to GHRP-6 were present in dw/dw females and could be induced in males by E 2 , the effects of GHRP-6 and TRH were also tested in Ovx dw/dw female rats and compared with those in sham-operated dw/dw controls (Fig. 3) . The effects of ovariectomy on PRL responses were dramatic; basal PRL levels were reduced, and the responses to both GHRP-6 and TRH were abolished (Fig. 3A) . The effects on GH, measured in the same samples, were in the same direction but were much less marked. Basal GH levels were the same in all groups, but ovariectomy significantly reduced the GH responses to GHRP-6 and TRH compared with those in the sham-operated dw/dw rats (Fig. 3B) .
Effects of GHRP-6 on TSH release
An obvious candidate mechanism for PRL release by GHRP-6 is a stimulation of hypothalamic TRH release. As this would also be expected to stimulate TSH, plasma TSH responses to GHRP-6 and TRH were also measured in young normal and dw/dw males, with and without E 2 treatment (Fig.  4 ). GHRP-6 had no effect on TSH release in any group, whereas TRH increased plasma TSH in all groups, with higher responses in the normal rats than in the dw/dw animals regardless of whether they were treated with E 2 . The lack of TSH response to GHRP-6 but not TRH, and the lack of an induction of TSH responses to GHRP-6 after E 2 suggest that the effects of GHRP-6 on PRL in dw/dw rats are not mediated via TRH release.
Effects of E 2 treatment on hypothalamic GHS-R expression
As the effects of GHRP-6 on PRL release were increased by E 2 treatment, an additional group of eight adult normal male rats was treated with E 2 (25 g/day for 14 days), and their hypothalamic GHS-R messenger RNA (mRNA) expression was evaluated by in situ hybridization. Individual examples are illustrated in Fig. 5A , and the results of quantitation in VMN and ARC of all animals are shown in Fig. 5B . The overall hypothalamic distribution of specific GHS-R mRNA expression was unaffected by E 2 treatment, and no new sites of expression were noted compared with those in shamtreated controls. However, the abundance of GHS-R mRNA was significantly increased in both ARC and VMN of E 2 -treated animals compared with that in untreated controls. Similar increases in ARC GHS-R expression were observed FIG. 2. The effects of E 2 treatment on PRL and GH responses to GHRP-6 and TRH. Groups (n ϭ 12) of young normal (left panels) or dwarf (right panels) male rats were anesthetized and given iv injections of GHRP-6 (0.5 g) followed 3 h later by TRH (1 g). Six animals from each strain received E 2 treatment from sc pellets implanted 14 days previously (f and F), whereas the other six received sham implants (Ⅺ and E). Blood samples were withdrawn and assayed for PRL (A and B) or GH (C and D) as before. The data shown are the mean Ϯ SEM. **, P Ͻ 0.01; ***, P Ͻ 0.001 (E 2 treated vs. sham-treated rats).
in 12 female rats given the same E 2 treatment for 14 days (not shown).
Discussion
Although early studies with GHRP-6 showed that this secretagogue was relatively specific for GH release in rats, subsequent investigations in humans revealed slight but significant stimulation of ACTH and PRL by a variety of GH secretagogues (see Refs. 4 and 35 for review). The mechanisms involved in GHS-stimulated GH release in vivo are complex, but are much better understood than the mechanisms mediating other endocrine effects of these compounds. We and others have recently investigated ACTH stimulation by GHSs and have suggested that, as for GH release, the major site of action is hypothalamic (22, 31) , probably involving endogenous ACTH secretagogues (16) , although this may differ between species (19) .
PRL responses to GH secretagogues are also observed in human subjects (12, 13, 15, 18, 20, 23, 24) , but there is no information about the mechanisms involved. PRL responses are much less prominent in conscious experimental animals (1, 14, 25) and thus are difficult to study. As GH responses to GHRP-6 are greater in young female rats than in older males (32, 33) and are more reproducible in anesthetized than in conscious rats, we compared the PRL and GH responses to GHRP-6 and TRH in both young and adult male and female animals under anesthesia. PRL responses were also studied in dw/dw rats, as these animals are fully responsive to the hypothalamic effects of GHRP-6 (27) and show increased hypothalamic expression of the newly identified GHS-R (9). Furthermore, unlike other dwarf rodent models, dw/dw rats maintain high PRL production and lactotroph numbers in the face of profound GH deficiency and somatotroph hypoplasia. In our initial description of this dw/dw rat (26), we found pituitary PRL concentrations unchanged although total PRL contents were reduced compared with those in heterozygous animals. Our more extensive studies suggested that PRL concentrations are actually increased in these rats (28) .
We show here for the first time that female dw/dw rats release PRL at doses of GHRP-6 that produce no significant PRL release in male normal or dw/dw rats. Furthermore, PRL responses to GHRP-6 are sensitive to E 2 . They were eliminated in dw/dw females by ovariectomy and were induced in dw/dw males by E 2 treatment. This study is also the first to examine PRL responses to TRH in the dw/dw strain, which were enhanced compared with those in normal females of the same strain. As in normal males, PRL release in dw/dw male rats was relatively unresponsive to TRH, but a strong PRL response to both TRH and GHRP-6 was induced in dw/dw males by treating them with E 2 .
The effectiveness of GHRP-6-induced GH release in rats is affected by the gonadal steroid environment (4, 32, 33 ). Mallo
FIG. 3. Effects of ovariectomy on PRL and GH responses to GHRP-6
and TRH in female dw/dw rats. Groups of six sham-operated (F) and five Ovx (E) dw/dw female rats were anesthetized and given iv injections of GHRP-6 (0.5 g) followed 3 h later by TRH (1 g) as before. Blood samples were withdrawn and assayed for PRL (A) or GH (B). The data shown are the mean Ϯ SEM. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001 (Ovx vs. sham-operated controls).
FIG. 4. The effects of E 2 treatment on TSH responses to GHRP-6 and
TRH in normal and dw/dw male rats (same experiment as that in Fig.  2 ). Blood samples were assayed for TSH after iv administration of GHRP-6 (0.5 g) followed 3 h later by TRH (1 g). Groups (n ϭ 12) were either normal (Ⅺ and f) or dw/dw (E and F) young male rats; six animals in each group (f and F) had received E 2 treatment for 14 days, and the others (Ⅺ and E) were given sham implants. The data shown are the mean Ϯ SEM. **, P Ͻ 0.01, AS vs. dw/dw; †, P Ͻ 0.05, E 2 -treated vs. nontreated normal rats.
et al. (34) reported that the GH responses to GHRP-6 were reduced by gonadectomy in adult males, but could be increased by testosterone or E 2 treatment. In intact adult males, E 2 increased the GH response to GHRP-6 (34), whereas it decreased the response to GHRH. We found no change in GH release after GHRP-6 treatment in normal adult rats and a small diminution in dw/dw rats after E 2 treatment. Studies in adult human subjects show no major sex differences in GH responses to GHRP-6 (35), which are similar across the menstrual cycle (36) and are unaltered by E 2 treatment in postmenopausal women (37) . On the other hand, GH responses to the GHRP-6 analog, hexarelin, are greater in girls than in boys at puberty (38) .
In contrast to their effects on GH, the effects of gonadal steroids on PRL responses to GHRP-6 have not been investigated. Although there was little effect of E 2 on PRL responses to GHRP-6 in normal rats, the PRL response in dw/dw rats was clearly dependent on E 2 and could be differentiated from the effects on GH. Ovariectomy drastically reduced their PRL responses while leaving their GH responses intact, whereas E 2 treatment induced a robust PRL response to GHRP-6 in dw/dw males while inhibiting their GH responses to GHRP-6.
How might the PRL-releasing effect of GHRP-6 be mediated? For GH release, GHRP-6 acts in part by releasing GHRH, with which it synergizes (39, 40) . However, GHRH is unlikely to mediate GHRP-6-induced PRL release, as GHRH administration produced robust GH release without affecting PRL in either normal or dw/dw strains, and GHRH does not synergize with hexarelin on PRL release as it does for GH (18, 40) .
An analogous possibility was that GHRP-6-induced PRL release could be mediated via a stimulation of TRH release, especially as the PRL responses to TRH were affected by E 2 treatment and ovariectomy in exactly the same fashion as those to GHRP-6. However, TRH and GHRP-6 do not interact on each other's receptors (7, 41) , no increase in TSH was observed after GHRP-6 administration in rats that showed strong TSH responses to TRH, nor did E 2 treatment induce a TSH response to GHRP-6. Although the GHS hexarelin has similar ED 50 values for inducing PRL and GH release in man (18) , this secretagogue produces a much smaller PRL response than does TRH (42) . Furthermore, TSH is either unaffected or decreased by GHS administration in human subjects (43, 44) . We thus believe it unlikely that GHRP-6 releases PRL in the rat simply by releasing TRH.
We cannot rule out the possibility that lactotrophs and thyrotrophs in dw/dw rats are differentially sensitive to TRH, or that GHRP-6 might release another factor, such as somatostatin, that could block the effects of TRH on TSH but leave PRL responses unaffected. Again, this is unlikely, as the sensitivity of PRL to somatostatin inhibition in the rat is increased, not decreased, by E 2 treatment (45).
GHRP-6 could also stimulate PRL release by inhibiting the output of dopamine (DA) from tuberoinfundibular dopaminergic (TIDA) neurons in the ARC or by functionally antagonizing DA at the pituitary. Enhanced PRL responses in E 2 -treated animals might then be explained by their increased TIDA DA synthesis and metabolism (46) . Although many ARC cells are stimulated by GHSs (10, 47) , other cells are inhibited (10) , although these may not project to the median eminence (48) . Few of the cells that respond to GHRP-6 with increased c-fos expression contain tyrosine hydroxylase (47), although c-fos expression may not be a good marker for revealing cells inhibited by GHRP-6. TIDA cell immunofluorescence is unchanged in dw/dw rats despite their high pituitary PRL stores (49) , and GHRP-6-induced PRL release in anesthetized dw/dw females is not affected by pretreatment with DA antagonists (Carmignac, D. F., unpublished data), so an inhibition of TIDA cell activity in dw/dw rats by GHRP-6 is unlikely to explain an acute PRL response.
The simplest explanation of our results is that GHRP-6-induced PRL release in anesthetized rats is a direct pituitary effect, insignificant in males, more pronounced in females or after E 2 treatment in males, and greatest in dw/dw rats, which have increased pituitary PRL cells relative to GH cells (49) . As the PRL responses to TRH and GHRP-6 were affected by E 2 and ovariectomy in the same way, both peptides may act on the same population of E 2 -sensitive PRL-producing cells, which is prominent in dw/dw rats.
It is well established that E 2 increases lactotroph TRH receptor expression, PRL responsiveness to TRH, and PRL synthesis (50, 51) . The latter effect would increase the amount of PRL available for release by GHRP-6. E 2 can also affect PRL responses to TRH indirectly, as TRH is degraded by a pitu- itary enzyme activity that is reduced by E 2 treatment (52). However, unless this enzyme also degrades GHRP-6, this would not explain the heightened PRL response to this secretagogue after E 2 treatment.
Our study cannot distinguish an effect of E 2 on lactotrophs (to render their PRL release GHRP-6 responsive), from an effect of E 2 on somatomammotrophs (to secrete both GH and PRL in response to GHRP-6 and TRH). We favor the latter hypothesis, because the animals that showed the most pronounced PRL responses to GHRP-6 (female dw/dw rats or male dw/dw rats treated with E 2 ) also showed small GH responses to TRH. Furthermore, the PRL responses to TRH and GHRP-6 were both abolished in Ovx dw/dw females, whereas the GH responses to GHRP-6 (most of which we assume derive from somatotrophs) were unchanged.
Although all pituitary cells exhibiting GHS binding apparently contain some GH (4) , not all GH-containing cells respond to GHSs, and subpopulations of GH-containing cells have been described that differ in their responses to GHRP-6 or GHRH (53) . Other data also suggest that PRL release induced by GHRP-6 is direct and derives mainly from somatomammotrophs. PRL responses to GHSs can be observed in vitro and are more pronounced in pituitary cells from lactating rats (4), which have an increased proportion of somatomammotrophs (54) . Furthermore, E 2 treatment increases somatomammotroph cell numbers (45, 54, 55) .
The small GH response to TRH we observed in some animals accords with the observation that 7% of rat pituitary cells responding to GHRP-6 also respond to TRH (4). Paradoxical GH responses to TRH are also observed in acromegaly and in critical illness, conditions in which PRL responses to GHSs may also be demonstrated (15, 24, 56) , although PRL was not responsive to hexarelin in patients with idiopathic hyperprolactinemia (24) .
We also examined the effects of E 2 on GHS-R expression because this treatment had opposite effects on GH and PRL responses to GHRP-6. We have previously found it difficult to reveal specific GHS-R expression in the pituitary gland using in situ hybridization (9), whereas GHS-R expression is readily demonstrable in the hypothalamus under the same conditions. In that study (9), a sex difference in GHS-R expression was found in VMN but not in ARC. In the present study, no additional sites of hypothalamic GHS-R expression were revealed after E 2 administration, but we show here that the levels of GHS-R mRNA in both ARC and VMN were strongly up-regulated in E 2 -treated rats.
An increased GH response to GHS in short normal children given priming doses of testosterone or E 2 was not seen when a nonaromatizable androgen was used (57), implicating a specific estrogenic effect on the GH response to GHSs, and the researchers speculated that E 2 could increase hypothalamic GHS-R expression. Our results provide direct evidence in favor of this and might also explain why GHRP-6 responses are more pronounced in female rats (32, 33) . However, in our study, it was the PRL, rather than GH, responses to GHRP-6 that were increased by E 2 . As GHSs also have other nonendocrine effects (such as stimulation of food intake) that are also sensitive to E 2 , it is unwise to interpret changes in hypothalamic GHS-R expression induced by E 2 solely in terms of effects on the GH axis.
These studies were largely focused on anesthetized female dw/dw rats, simply because they exhibit the most robust PRL responses to GHRP-6. However, PRL responses to GHRP-6 are demonstrable in conscious female rats and also in conscious male dw/dw rats treated with E 2 (Thomas, G. B., D. F. Carmignac, and I. C. A. F. Robinson, unpublished observations). Thus, although the PRL responses to GHRP-6 depend heavily on the gender, GH status, and gonadal steroid milieu in the rat, they are not simply a consequence of anesthesia. In human subjects, PRL responses to GHSs are usually observed, but the plasma concentrations generally remain within the normal physiological range (12) , so the physiological or clinical significance of this response may be questioned. Nevertheless, most clinical studies with these agents have been performed in male subjects; our results suggest that PRL responses to GH secretagogues in GH-deficient female subjects should be given further attention.
